Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.
Yanxia GuoAlice M WalshMary CanavanMihir D WechalekarSuzanne ColeXuefeng YinBrittney ScottMathew LozaCarl OrrTrudy McGarryMichele BombardieriFrances HumbySusanna M ProudmanCostantino PitzalisMalcolm D SmithJoshua R FriedmanIan AndersonLoui MadakamutilDouglas J VealeUrsula FearonSunil NagpalPublished in: PloS one (2018)
Immune checkpoint blockade with therapeutic anti-cytotoxic T lymphocyte-associated antigen (CTLA)-4 (Ipilimumab) and anti-programmed death (PD)-1 (Nivolumab and Pembrolizumab) antibodies alone or in combination has shown remarkable efficacy in multiple cancer types, concomitant with immune-related adverse events, including arthralgia and inflammatory arthritis (IA) in some patients. Herein, using Nivolumab (anti-PD-1 antagonist)-responsive genes along with transcriptomics of synovial tissue from multiple stages of rheumatoid arthritis (RA) disease progression, we have interrogated the activity status of PD-1 pathway during RA development. We demonstrate that the expression of PD-1 was increased in early and established RA synovial tissue compared to normal and OA synovium, whereas that of its ligands, programmed death ligand-1 (PD-L1) and PD-L2, was increased at all the stages of RA disease progression, namely arthralgia, IA/undifferentiated arthritis, early RA and established RA. Further, we show that RA patients expressed PD-1 on a majority of synovial tissue infiltrating CD4+ and CD8+ T cells. Moreover, enrichment of Nivolumab gene signature was observed in IA and RA, indicating that the PD-1 pathway was downregulated during RA disease progression. Furthermore, serum soluble (s) PD-1 levels were increased in autoantibody positive early RA patients. Interestingly, most of the early RA synovium tissue sections showed negative PD-L1 staining by immunohistochemistry. Therefore, downregulation in PD-1 inhibitory signaling in RA could be attributed to increased serum sPD-1 and decreased synovial tissue PD-L1 levels. Taken together, these data suggest that agonistic PD1 antibody-based therapeutics may show efficacy in RA treatment and interception.
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- interstitial lung disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- cell proliferation
- squamous cell carcinoma
- genome wide
- poor prognosis
- transcription factor
- patient reported outcomes
- cancer therapy
- peripheral blood
- electronic health record
- lymph node metastasis
- childhood cancer
- flow cytometry